Anita Rijneveld, MD, Erasmus MC, Rotterdam, Netherlands, comments on the results of HOVON-100, a Phase III study evaluating the impact of the addition of clofarabine to standard induction and consolidation therapy on the outcomes of adult patients with acute lymphoblastic leukemia (ALL). Whilst the trial reported that patients treated with clofarabine had higher measurable residual disease (MRD) negativity rates, it did not translate to better outcomes, which was probably due to the toxicity of this agent. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.